Welcome to our dedicated page for Liminatus Pharma SEC filings (Ticker: LIMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liminatus Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liminatus Pharma's regulatory disclosures and financial reporting.
Liminatus Pharma, Inc. reports that Nasdaq has notified the company it has not regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1 per share for 30 consecutive business days, and that it is not eligible for a second 180-day extension to cure the deficiency. A hearing was held before the Nasdaq Hearings Panel on June 30, 2026, and the Panel will consider this additional deficiency in deciding on the company’s continued listing; Liminatus plans to submit a written response by July 27, 2026, and the Panel has not yet issued its decision.
The company also filed a definitive proxy statement on July 13, 2026, for an annual stockholder meeting on August 3, 2026, to consider authorizing the board of directors to approve a reverse stock split of its common stock, among other matters. Liminatus cautions that there can be no assurance it will receive additional time or regain compliance with Nasdaq’s bid-price requirements.
Samda Biolab Co., Ltd. reported beneficial ownership of Common Stock of Liminatus Pharma, Inc.. Samda Biolab holds 3,426,548 shares of Common Stock, representing 5.1% of the class, based on 67,160,362 shares outstanding as of July 2, 2026.
Samda Biolab has sole voting and sole dispositive power over all 3,426,548 shares, with no shared voting or dispositive power reported.
Liminatus Pharma, Inc. reported that Valetudo Therapeutics LLC, a greater-than-10% holder controlled by CEO Chris Kim, received 3,448,926 shares of common stock and 48,975.10742 shares of Series A Non-Voting Convertible Preferred Stock as consideration in the acquisition of InnocsAI LLC. Following the transaction, Valetudo holds 5,244,351 common shares and a preferred position convertible into 489,751,074 common shares, with each preferred share convertible into 10,000 common shares at an issue price of $0.20 per share. Conversion of the preferred stock is contingent on prior stockholder approval under applicable Nasdaq Stock Market LLC listing rules. Kim may be deemed the beneficial owner of Valetudo’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Valetudo Therapeutics LLC and Chris Kim report significant ownership in Liminatus Pharma, Inc. They beneficially own 9,617,954 shares of common stock, representing 14.3% of the outstanding class, based on 67,160,362 shares of common stock outstanding as of July 2, 2026.
The position includes 5,244,351 common shares held directly by Valetudo and 4,373,603 common shares held by Ewon Comfortech Co., Ltd., over which Valetudo has voting power under a voting agreement. Chris Kim, the issuer’s Chief Executive Officer, director and controlling member of Valetudo, may be deemed to beneficially own these shares, subject to a pecuniary-interest disclaimer.
On June 24, 2026, Valetudo transferred 4,373,603 shares to Ewon Comfortech while retaining voting power. On July 2, 2026, Valetudo received 3,448,926 common shares and 48,975.10742 shares of Series A Non-Voting Convertible Preferred Stock as consideration in the acquisition of InnocsAI LLC. Each preferred share is convertible into 10,000 common shares, contingent on prior stockholder approval under Nasdaq Stock Market LLC listing rules, and has no expiration date. The reported holdings are held for investment, with flexibility to buy or sell in the future.
Liminatus Pharma, Inc. is calling a 2026 annual stockholder meeting on August 3, 2026 to vote on three main items: electing two Class I directors (Nicholas Fernandez and Dr. Ji Yeon Baek), ratifying WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026, and authorizing the Board to implement a reverse stock split of up to 1-for-50 and related charter amendment to help meet Nasdaq or other exchange listing requirements.
There were 67,160,362 shares of common stock outstanding as of the July 2, 2026 record date, with one vote per share and no cumulative voting. Significant holders include Valetudo Therapeutics LLC at 14.3%, Samda Biolab Co., Ltd. at 5.1%, and Ewon Comfortech Co., Ltd. at 8.2%. The company recently acquired InnocsAI LLC, issuing 11,188,729 common shares and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock, each convertible into 10,000 common shares after required stockholder approval. CEO Chris Kim received salary of $183,333 in 2025 and has $0.21 million in deferred compensation accrued.
Liminatus Pharma insider filing reports an internal share transfer by a major holder. Valetudo Therapeutics LLC, a ten percent owner associated with CEO and director Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no payment of consideration.
Valetudo retains voting power over the transferred shares under a voting agreement and continues to hold 1,795,803 shares of Liminatus Pharma common stock of record. Kim may be deemed the beneficial owner through his control of Valetudo but disclaims beneficial ownership beyond his ultimate pecuniary interest.
Ewon Comfortech Co., Ltd. has filed an initial ownership report for Liminatus Pharma, Inc., showing holdings of 5,500,000 shares of common stock. A footnote explains that 4,373,603 of these shares were transferred from Valetudo Therapeutics LLC, which retains voting power over those shares under a voting agreement.
Liminatus Pharma, Inc. received a Schedule 13G/A disclosure showing that Ewon Comfortech Co., Ltd. beneficially owns 5,500,000 shares of Common Stock, representing 10.9% of the class based on 55,971,633 shares outstanding as of July 1, 2026. The filing reports sole voting power of 1,126,397 shares and sole dispositive power over 5,500,000 shares. The amendment is signed by Joo Sung Park, CEO on 07/06/2026.
Liminatus Pharma, Inc. has amended its merger agreement with InnocsAI LLC and completed the acquisition through a new subsidiary. The revised structure splits the 1,600,000,000-share merger consideration between common stock and new Series A Non-Voting Convertible Preferred Stock so closing could occur before stockholder approval. At closing, former InnocsAI members received 11,188,729 common shares and 158,881.1271 Series A Preferred shares, with common limited to an estimated 19.99% of outstanding stock immediately before closing under Nasdaq rules. Each Series A share is convertible into 10,000 common shares only after stockholders approve the underlying issuance. Liminatus granted InnocsAI holders Form S-3 and piggy-back registration rights and entered into two-year non-compete and non-solicitation agreements with key InnocsAI employees. The Series A Preferred participates in dividends on an as-converted basis, ranks on parity with common stock in liquidation, is non-voting except as provided by law, and is not redeemable.
Liminatus Pharma, Inc. is seeking shareholder approval to authorize its Board to implement a reverse stock split of up to 1-for-50 and to amend the company’s certificate of incorporation to reflect the split. The Board says the Reverse Stock Split is intended primarily to satisfy Nasdaq’s minimum bid price requirement and to support a continued listing.
The proposal would let the Board select the final Ratio (up to 1-for-50) without further stockholder action. Based on 50,607,633 shares outstanding as of the Record Date, a 1-for-50 split would reduce shares outstanding to approximately 1,012,153. Fractional shares would be rounded up to whole shares. The Annual Meeting also seeks votes to elect two directors and to ratify WithumSmith+Brown, PC as auditor.